Actively Recruiting

Phase Not Applicable
Age: 0 - 18Years
All Genders
NCT06775457

Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)

Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-15

120

Participants Needed

5

Research Sites

237 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Human Endogenous Retroviruses (HERVs) are ancient sequences that became integrated into our DNA during evolutionary processes. The significance of their presence in DNA is still being studied, but HERVs appear to be involved in the regulation of the immune response. The gut microbiota is the set of microorganisms that physiologically colonize the gastrointestinal tract. Progressively increasing attention is being paid to the gut microbiota and its potential role in diseases of various kinds. In particular, it has recently been shown how abnormalities in the microbiota can affect immune regulation by determining the occurrence of certain diseases. One objective of the study is to evaluate whether there is an association between the expression of HERVs and clinical manifestations in pediatric age in patients with various diseases such as Kawasaki Disease, IgA Vasculitis/Schonlein-Henoch's Purpura, SARS-CoV-2 infection, or, finally, febrile virosis. Another objective of the study is to evaluate whether there is an association between the presence of particular types of bacteria in the gut microbiota and clinical manifestations in pediatric age in patients with Kawasaki Disease, IgA Vasculitis/Schonlein-Henoch purpura, SARS-CoV-2 infection or febrile virosis. The results from this may open new perspectives for both the care and therapeutic management of children with these diseases.

CONDITIONS

Official Title

Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)

Who Can Participate

Age: 0 - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pediatric patients newly diagnosed with Kawasaki disease
  • Pediatric patients newly diagnosed with Vasculitis
  • Pediatric patients newly diagnosed with SARS-CoV-2 infection
  • Pediatric patients newly diagnosed with febrile virosis
  • Pediatric patients with inflammatory diseases with systemic involvement
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Ospedale Ramazzini di Carpi, Azienda USL di Modena UO Pediatria

Carpi, Modena, Italy, 41012

Actively Recruiting

2

IRCCS Azienda Ospedaliero - Universitaria di Bologna, U.O. Pediatria d'Urgenza, Pronto Soccorso e Osservazione Breve ed Intensiva

Bologna, Italy, 40138

Actively Recruiting

3

Azienda Ospedaliera-Universitaria di Modena

Modena, Italy, 41100

Actively Recruiting

4

IRCCS Ospedale Pediatrico Bambino Gesù UOC Pediatria Generale

Roma, Italy, 00165

Actively Recruiting

5

Ospedale Regina Margherita, Torino, UO Reumatologia Pediatrica

Torino, Italy, 10126

Actively Recruiting

Loading map...

Research Team

M

Marianna Fabi, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here